Bibliographic citations
Aronés, I., Galvez, C. (2023). Eficacia de los antidepresivos ISRS de acuerdo al tipo de interacción con tamoxifeno en mujeres con cáncer de mama RE+ con diagnóstico de depresión, una revisión sistemática [Tesis, Universidad Peruana de Ciencias Aplicadas (UPC)]. http://hdl.handle.net/10757/667533
Aronés, I., Galvez, C. Eficacia de los antidepresivos ISRS de acuerdo al tipo de interacción con tamoxifeno en mujeres con cáncer de mama RE+ con diagnóstico de depresión, una revisión sistemática [Tesis]. PE: Universidad Peruana de Ciencias Aplicadas (UPC); 2023. http://hdl.handle.net/10757/667533
@misc{renati/404659,
title = "Eficacia de los antidepresivos ISRS de acuerdo al tipo de interacción con tamoxifeno en mujeres con cáncer de mama RE+ con diagnóstico de depresión, una revisión sistemática",
author = "Galvez Fernandez, Claudia Isabel",
publisher = "Universidad Peruana de Ciencias Aplicadas (UPC)",
year = "2023"
}
Objectives: to evaluate the efficacy of SSRI antidepressants according to the type of interaction with tamoxifen in women with ER+ breast cancer and a diagnosis of depression. Compare the serum concentration of the active metabolite of tamoxifen, endoxifen. Materials and methods: a systematic review was carried out in the PubMed, Cochrane, SCOPUS, EBM (Ovid), OVID MEDLINE, Google Scholar, Lilacs, Web of Science, Clinical Trials, EBSCO, and EMBASE databases up to January 2023. Cohort-type studies were included that evaluated to women with early stage ER+ breast cancer (I and II) being treated with tamoxifen and diagnosed with depression. The data review process was carried out in two phases. Risk of bias was assessed using the New-Castle Ottawa tool. Quantitative results from cohort studies were combined using a forest plot following random effects models to better address the heterogeneity of population characteristics between studies. Results: three cohort studies were included. It was found that women with breast cancer who take antidepressants with a strong interaction have a lower endoxifen concentration of 7.64 ng/ml, p=0.001 95% CI (-12.23, -3.05). In one of the studies, the final concentration of endoxifen did not exceed the therapeutic response threshold. Conclusions: it cannot be affirmed that mildly interacting antidepressants cause improvement in depressive symptoms and a higher concentration of endoxifen based on the available evidence.
This item is licensed under a Creative Commons License